

**FORM 27**

**SECURITIES ACT**

**MATERIAL CHANGE REPORT UNDER  
SUBSECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)  
SUBSECTION 75(2) OF THE SECURITIES ACT (ONTARIO)  
SECTION 73 OF THE SECURITIES ACT (QUEBEC)**

Item 1. Name and Address of Reporting Issuer

Inflazyme Pharmaceuticals Ltd.  
425-5600 Parkwood Way  
Richmond, B.C.  
V6V 2M2

Item 2. Date of Material Change

March 20, 2000

Item 3. Press Release

A press release announcing the material change referred to in this report was issued on March 20, 2000.

Item 4. Summary of Material Change

The Issuer announced that it had closed on the final placement of convertible preferred shares with Aventis Pharma, the pharmaceutical company of Aventis S.A. (formerly Hoechst Marion Roussel) for net proceeds of CDN\$5,822,120. Proceeds will be used by the Issuer to fund the development of its IPL576 series in asthma and Aventis Pharma's H<sub>1</sub>/NK<sub>1</sub> series for the treatment of allergies.

Item 5. Full Description of Material Change

See press release issued on March 20, 2000.

Item 6. Confidential Report

Not applicable.

Item 7. Omitted Information

Not applicable.

Item 8. Senior Officer

For further information, please contact Mr. Jeffrey A. Bacha, Vice-President of Corporate Development at 1 (800) 315-3660.

Item 9. Statement of Senior Officer

The foregoing accurately discloses the material change referred to herein.

DATED as of this 20th day of March, 2000 in the City of Richmond, in the Province of British Columbia.

**INFLAZYME PHARMACEUTICALS LTD.**

*“Michael Liggett”*